COPD treatment can involve much more than inhalers. Depending on symptoms, previous flare-ups, oxygen levels, and other individual factors, management may include bronchodilator medications, pulmonary rehabilitation, smoking cessation, oxygen therapy, advanced procedures, and newer targeted drugs. Understanding both standard options and newer innovations can make it easier to discuss an individualized COPD management plan with a healthcare provider.
Bronchodilators and Inhaled COPD Medications
Bronchodilators are a major component of COPD treatment because they relax muscles surrounding the airways, helping keep them open. Short-acting inhaled medicines may be prescribed for rapid symptom relief, while long-acting bronchodilators are generally used regularly to maintain better control. Long-acting beta2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) may be prescribed individually or together, depending on a person’s symptoms and treatment needs (source).
Some patients may receive an inhaled corticosteroid as part of combination treatment, particularly when their history and disease characteristics suggest that an anti-inflammatory component may be beneficial. Combination inhalers can deliver two or three medications through one device. Correct inhaler technique matters because different devices operate differently, and improper use can reduce the amount of medication reaching the lungs (source).
Pulmonary Rehabilitation and Lifestyle Treatment
Pulmonary rehabilitation combines supervised exercise with education and strategies for managing chronic lung disease. Programs may also include breathing techniques, nutrition guidance, and other forms of support. Rehabilitation can help people become more active, manage breathlessness, and improve quality of life, and some programs are available through outpatient centers or remotely (source).
Stopping smoking is another central part of treatment for people who currently smoke. Continuing exposure to tobacco smoke can contribute to further lung damage and worsening symptoms. COPD management can also include maintaining physical activity where appropriate, following an exacerbation action plan, and staying engaged with routine medical care rather than relying on medication alone (source).
Oxygen and Support for More Advanced COPD
Supplemental oxygen may be prescribed when testing shows that blood oxygen levels are too low. Oxygen can be delivered through equipment used at home or in other settings, but it is not automatically appropriate for everyone with COPD. A healthcare professional determines whether oxygen is needed based on clinical testing and the person’s individual condition (source).
Some people with more advanced disease may require additional respiratory support. Noninvasive ventilation can be considered for selected patients, while severe COPD that remains difficult to manage may lead specialists to evaluate procedures such as bullectomy or bronchoscopic interventions. Lung transplantation is another option for carefully selected people with very severe disease (source).
Ensifentrine Adds a New Type of Maintenance Therapy
Newer COPD medications are expanding beyond traditional inhaler classes. Ensifentrine, marketed as Ohtuvayre, received FDA approval in 2024 for maintenance treatment of COPD in adults. It inhibits both phosphodiesterase 3 and phosphodiesterase 4 and is delivered by oral inhalation with a standard jet nebulizer. It is a maintenance treatment rather than a medication for immediately relieving an acute episode of bronchospasm (source).
This approval gives clinicians another option when constructing a maintenance regimen. As with other COPD medications, whether ensifentrine belongs in an individual’s treatment plan depends on their existing therapies, symptoms, medical history, potential adverse effects, and clinical assessment rather than simply on having a COPD diagnosis.
Biologics Bring Targeted Treatment to COPD
Biologic therapy represents another important recent development. Dupilumab is FDA-approved as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. Mepolizumab subsequently received a COPD indication in 2025 for adults with inadequately controlled disease and an eosinophilic phenotype. Neither is intended to replace rescue treatment during an acute breathing emergency (source; source).
These treatments illustrate the movement toward more targeted COPD care. Blood eosinophil measurements can help clinicians identify evidence of the type of inflammation relevant to biologic treatment. Biologics are added to an existing management plan for appropriate patients rather than serving as universal treatments for everyone with COPD (source).
Treatment Is Becoming More Individualized
Modern COPD management increasingly considers more than lung-function measurements alone. Symptoms, previous exacerbations, response to current medication, inhaler technique, blood eosinophils, smoking status, other medical conditions, and the ability to use particular delivery devices can all influence treatment decisions. Current management strategies distinguish between initial treatment and adjustments made when symptoms or exacerbations continue despite therapy (source).
That individualized approach is particularly important as the number of available therapies grows. A newer drug is not automatically preferable to established treatment, and some therapies are intended only for specific groups of patients. Regular reassessment allows clinicians to determine whether treatment is controlling symptoms, reducing flare-ups, and remaining practical for the person using it.
Understanding Today’s COPD Treatment Options
COPD treatment now spans established inhaled medicines, smoking cessation, pulmonary rehabilitation, oxygen and respiratory support, advanced procedures, and newer pharmacologic options. For appropriate patients, ensifentrine introduces a different maintenance mechanism, while dupilumab and mepolizumab bring targeted biologic therapy into COPD care.
The expanding range of therapies makes accurate diagnosis and individualized treatment selection increasingly important. Rather than relying on one medication or one measure of disease severity, COPD management can combine treatments according to symptoms, exacerbation history, inflammatory characteristics, oxygen needs, and overall health. Working with a healthcare professional to review these factors remains essential when deciding which established or newer therapies are appropriate.